Bolivia vs Vietnam: Average cost of drugs for extensively drug-resistant tuberculosis
Bolivia
753 constant 2022 US$
in 2024
Vietnam
807 constant 2022 US$
in 2024
Bolivia rank
48th
Vietnam rank
46th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bolivia
- Vietnam
How they compare
Vietnam currently reports 807 constant 2022 US$ against 753 constant 2022 US$ in Bolivia, a difference of 54 constant 2022 US$.
That makes Vietnam's figure about 1.1 times Bolivia's.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Bolivia ahead.
Bolivia ranks 48th and Vietnam ranks 46th of 56 countries.
Bolivia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bolivia | Vietnam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,803 constant 2022 US$ | 4,643 constant 2022 US$ | 5,160 constant 2022 US$ | Bolivia |
| 2020s | 8,250 constant 2022 US$ | 1,139 constant 2022 US$ | 7,111 constant 2022 US$ | Bolivia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bolivia or Vietnam?
- Vietnam, at 807 constant 2022 US$ against 753 constant 2022 US$ in Bolivia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bolivia and Vietnam?
- 54 constant 2022 US$, with Vietnam ahead.
- How many years of comparable data are there for Bolivia and Vietnam?
- 6 years are reported by both, from 2017 to 2024.
- How do Bolivia and Vietnam rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bolivia ranks 48th and Vietnam ranks 46th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.